SCHEMBL137219

SCHEMBL137219

CC(=O)N1CCC(=O)CC1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 1/20 0.46
NOTUM Q6P988 2/20 0.45
PTAFR P25105 1/20 0.43
PIK3CD O00329 1/20 0.40
LIPE Q05469 1/20 0.40
CASP6 P55212 1/20 0.39
GFER P55789 1/20 0.39
ALDH1A1 P00352 2/20 0.38
HPGD P15428 1/20 0.38
KMT2A Q03164 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL641829 0.91 CYP1A2 (0.43) CYP1A2TDP1SMN1; SMN2KDM4ENOTUM
SCHEMBL7379323 0.85
SCHEMBL11070126 0.84 CYP1A2 (0.50) CYP1A2TDP1SMN1; SMN2KDM4ENOTUM
SCHEMBL14720829 0.79 CYP1A2 (0.50) CYP1A2TDP1SMN1; SMN2KDM4ENOTUM
SCHEMBL15334705 0.79 LIPE (0.36) NOTUMLIPEALDH1A1KMT2A
SCHEMBL2161595 0.79 CYP1A2 (0.50) CYP1A2TDP1SMN1; SMN2KDM4ENOTUM
SCHEMBL24120035 0.78 LIPE (0.38) NOTUMLIPEALDH1A1KMT2A
SCHEMBL14344914 0.77 LIPE (0.35) NOTUMLIPEKMT2A
SCHEMBL17929144 0.77 LIPE (0.35) NOTUMLIPEKMT2A
SCHEMBL23552252 0.77 CYP1A2 (0.48) CYP1A2TDP1SMN1; SMN2KDM4ENOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513417-B2 Method for synthesis of nitroxyl radical KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2013-08-20 US claimed
WO-2008099198-A2 OSTEOGENIC COMPOUNDS INION LIMITED (GB) 2008-08-21 WO claimed
US-6436919-B1 LOCAL ANESTHETICS THAT HAVE LONGER DURATION OF ACTION WHILE REDUCING UNDESIRED SIDE EFFECTS THERAVANCE INC. 2002-08-20 US claimed
EP-1216243-A1 QUINAZOLINONES AND ANALOGUES AND THEIR USE AS LOCAL ANESTHETICS Advanced Medicine, Inc. (US) 2002-06-26 EP claimed
WO-2001025234-A1 QUINAZOLINONES AND ANALOGUES AND THEIR USE AS LOCAL ANESTHETICS ADVANCED MEDICINE, INC. (US) 2001-04-12 WO claimed
EP-0825183-B1 Process for the preparation of 1-acetyl-4-piperidinones BASF AG (DE) 2000-02-16 EP claimed
US-5861513-A Preparation of 1-acetyl-4-piperidones BASF AKTIENGESELLSCHAFT (DE) 1999-01-19 US claimed
EP-0431943-B1 Spiro(pyran)piperidine derivatives MERCK & CO INC (US) 1998-07-15 EP claimed
US-5665504-A Simulated photographic-quality prints using a plasticizer to reduce curl XEROX CORPORATION (US) 1997-09-09 US claimed
EP-0552360-A1 A COMPOSITION AND METHOD FOR SIMULTANEOUS ABSORPTION OF SULFUR DIOXIDE AND NITRIC OXIDE THE DOW CHEMICAL COMPANY (US) 1993-07-28 EP claimed
WO-1993003825-A1 A COMPOSITION AND METHOD FOR SIMULTANEOUS ABSORPTION OF SULFUR DIOXIDE AND NITRIC OXIDE THE DOW CHEMICAL COMPANY (US) 1993-03-04 WO claimed
US-5167941-A Sulfur dioxide; cationic polyelectrolyte stabilizers THE DOW CHEMICAL COMPANY (US) 1992-12-01 US claimed
EP-0219626-A2 Film-forming compositions comprising polyglutarimide International Business Machines Corporation (US) 1987-04-29 EP claimed
EP-0201366-A1 5-H-pyrido[3',4':4,5]pyrrolo[3,2-c]pyridines, process for their preparation and their use as synthesis intermediates SANOFI (FR) 1986-11-12 EP claimed
EP-0197829-A1 5H-pyrido[3',4':4,5]pyrrolo[3,2-c]pyridine derivatives, process for their preparation and their antitunour activity SANOFI (FR) 1986-10-15 EP claimed
US-4036842-A FRIEDEL CRAFTS CATALYST AMERICAN HOME PRODUCTS CORPORATION (US) 1977-07-19 US claimed
JP-10147571-A None JP disclosed
US-20260116855-A1 ORALLY ACTIVE MELANOCORTIN RECEPTOR-4 COMPOUNDS PALATIN TECHNOLOGIES INC (US) 2026-04-30 US disclosed
US-3932650-A TRANQUILIZERS E. I. DU PONT DE NEMOURS & COMPANY (US) 1976-01-13 US disclosed
US-3931169-A ANTIINFLAMMATORY E. R. SQUIBB & SONS, INC. (US) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260116855-A1 ORALLY ACTIVE MELANOCORTIN RECEPTOR-4 COMPOUNDS MC1R, MC3R, MC5R CYP1A2 2315/4885TDP1 4710/4885SMN1; SMN2 2085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.